248 results on '"Prado, Julia G."'
Search Results
2. Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals
3. Kinetics of humoral immune response over 17 months of COVID-19 pandemic in a large cohort of healthcare workers in Spain: the ProHEpiC-19 study
4. Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control
5. Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results.
6. Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection
7. Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial
8. Antibody cooperative adsorption onto AuNPs and its exploitation to force natural killer cells to kill HIV-infected T cells
9. Reduced Cortical Thickness Correlates of Cognitive Dysfunction in Post-COVID-19 Condition: Insights from a Long-Term Follow-up.
10. 3145 – NSGS MICE HUMANIZED WITH CORD BLOOD CD34NEG MONONUCLEAR CELLS SHOW SUSTAINED AND FUNCTIONAL MYELOID-LYMPHOID REPRESENTATION WITH LIMITED GRAFT-VERSUS-HOST-DISEASE
11. Selective loss of CD107a TIGIT+ memory HIV-1-specific CD8+ T cells in PLWH over a decade of ART
12. Author response: Selective loss of CD107a TIGIT+ memory HIV-1-specific CD8+ T cells in PLWH over a decade of ART
13. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial
14. Author Correction: Sex-specific innate immune selection of HIV-1 in utero is associated with increased female susceptibility to infection
15. Sex-specific innate immune selection of HIV-1 in utero is associated with increased female susceptibility to infection
16. Immune Selection for Altered Antigen Processing Leads to Cytotoxic T Lymphocyte Escape in Chronic HIV-1 Infection
17. Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction
18. Slow progression of pediatric HIV associates with early CD8+ T cell PD-1 expression and a stem-like phenotype
19. Slow progression of pediatric HIV associates with early CD8+ T cell PD-1 expression and a stem-like phenotype
20. Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa
21. Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution
22. Single-cell CD8+ dynamics in PLWH uncover the depletion of TIGIT+ memory HIV-1-specific cells during long-term ART
23. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial
24. Neurocognitive Profile of the Post-COVID Condition in Adults in Catalonia—A Mixed Method Prospective Cohort and Nested Case–Control Study: Study Protocol
25. Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors
26. Additional file 1 of Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control
27. Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals.
28. Kinetics of humoral immune response over 17 months of COVID-19 pandemic in a large cohort of healthcare workers in Spain: The ProHEpiC-19 study
29. Neurocognitive Profile of the Post-COVID Condition in Adults in Catalonia-A Mixed Method Prospective Cohort and Nested Case-Control Study : Study Protocol
30. Additional file 1 of Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control
31. Additional file 1 of Kinetics of humoral immune response over 17 months of COVID-19 pandemic in a large cohort of healthcare workers in Spain: the ProHEpiC-19 study
32. Viral and Cellular Factors Leading to the Loss of CD4 Homeostasis in HIV-1 Viremic Nonprogressors
33. Erratum for Puertas et al., “VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies”
34. VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies
35. Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report
36. Highly functional Cellular Immunity in SARS-CoV-2 Non-Seroconvertors is associated with immune protection
37. Antibody cooperative adsorption onto AuNPs and its exploitation to force natural killer cells to kill HIV-infected T cells
38. Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression
39. Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection
40. On behalf of ACT LifeSciCoP Life Science Community of Practice : A cross-institutional collaboration for cultural change towards gender equality
41. Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection
42. Life Science Community of Practice : A cross institutional collaboration for cultural change towards gender equality
43. HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD[4.sup.+] T cell counts but persistent virologic failure
44. Chapter 1 HLA‐Mediated Control of HIV and HIV Adaptation to HLA
45. A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors
46. SARS-CoV-2 Consensus-Sequence and Matching Overlapping Peptides Design for COVID19 Immune Studies and Vaccine Development
47. HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy
48. Editorial: Immune Surveillance of the HIV Reservoir: Mechanisms, Therapeutic Targeting and New Avenues for HIV Cure
49. HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells
50. Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.